FRIDAY, Oct. 4, 2024 — For patients with moderate-to-severe atopic dermatitis (AD), lebrikizumab has long-term efficacy, according to a study presented at the annual meeting of the European Academy of Dermatology and Venereology, held from Sept. 25…Original Article
Long-Term Efficacy for Lebrikizumab Seen in Moderate, Severe Eczema
FRIDAY, Oct. 4, 2024 — For patients with moderate-to-severe atopic dermatitis (AD), lebrikizumab has long-term efficacy, according to a study presented at the annual meeting of the European Academy of Dermatology and Venereology, held from Sept. 25…
